Stabilizing a nucleic acid for nucleic acid sequencing

Information

  • Patent Grant
  • 7220549
  • Patent Number
    7,220,549
  • Date Filed
    Thursday, December 30, 2004
    19 years ago
  • Date Issued
    Tuesday, May 22, 2007
    17 years ago
Abstract
The invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex on a substrate. Methods of the invention generally contemplate the use of a dual-anchored primer/target nucleic acid duplex, or a stabilizing molecule in a single molecule sequencing reaction.
Description
TECHNICAL FIELD OF THE INVENTION

The invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex attached to a substrate. Generally, methods of the invention comprise the use of a dual-anchored primer/target nucleic acid duplex or stabilizing molecule.


BACKGROUND OF THE INVENTION

Completion of the human genome has paved the way for important insights into biologic structure and function. Knowledge of the human genome has given rise to inquiry into individual differences, as well as differences within an individual, as the basis for differences in biological function and dysfunction. For example, single nucleotide differences between individuals, called single nucleotide polymorphisms (SNPs), are responsible for dramatic phenotypic differences. Those differences can be outward expressions of phenotype or can involve the likelihood that an individual will get a specific disease or how that individual will respond to treatment. Moreover, subtle genomic changes have been shown to be responsible for the manifestation of genetic diseases, such as cancer. A true understanding of the duplexities in either normal or abnormal function will require large amounts of specific sequence information.


An understanding of cancer also requires an understanding of genomic sequence duplexity. Cancer is a disease that is rooted in heterogeneous genomic instability. Most cancers develop from a series of genomic changes, some subtle and some significant, that occur in a small subpopulation of cells. Knowledge of the sequence variations that lead to cancer will lead to an understanding of the etiology of the disease, as well as ways to treat and prevent it. An essential first step in understanding genomic duplexity is the ability to perform high-resolution sequencing.


Various approaches to nucleic acid sequencing exist. One conventional way to do bulk sequencing is by chain termination and gel separation, essentially as described by Sanger et al., Proc. Natl. Acad. Sci., 74(12): 5463–67 (1977). That method relies on the generation of a mixed population of nucleic acid fragments representing terminations at each base in a sequence. The fragments are then run on an electrophoretic gel and the sequence is revealed by the order of fragments in the gel. Another conventional bulk sequencing method relies on chemical degradation of nucleic acid fragments. See, Maxam et al., Proc. Natl. Acad. Sci., 74: 560–564 (1977). Finally, methods have been developed based upon sequencing by hybridization. See, e.g., Drmanac, et al., Nature Biotech., 16: 54–58 (1998).


Bulk sequencing techniques are not useful for the identification of subtle or rare nucleotide changes due to the many cloning, amplification and electrophoresis steps that complicate the process of gaining useful information regarding individual nucleotides. The ability to sequence and gain information from single molecules obtained from an individual patient is the next milestone for genomic sequencing. As such, research has evolved toward methods for rapid sequencing, such as single molecule sequencing technologies.


There have been many proposals to develop new sequencing technologies based on single-molecule measurements, generally either by observing the interaction of particular proteins with DNA or by using ultra high resolution scanned probe microscopy. See, e.g., Rigler, et al., DNA-Sequencing at the Single Molecule Level, Journal of Biotechnology, 86(3): 161 (2001); Goodwin, P. M., et al., Application of Single Molecule Detection to DNA Sequencing. Nucleosides & Nucleotides, 16(5–6): 543–550 (1997); Howorka, S., et al., Sequence-Specific Detection of Individual DNA Strands using Engineered Nanopores, Nature Biotechnology, 19(7): 636–639 (2001); Meller, A., et al., Rapid Nanopore Discrimination Between Single Polynucleotide Molecules, Proceedings of the National Academy of Sciences of the United States of America, 97(3): 1079–1084 (2000); Driscoll, R. J., et al., Atomic-Scale Imaging of DNA Using Scanning Tunneling Microscopy. Nature, 346(6281): 294–296 (1990). Unlike conventional sequencing technologies, their speed and read-length would not be inherently limited by the resolving power of electrophoretic separation. Other methods proposed for single molecule sequencing include detecting individual nucleotides as they are incorporated into a primed template, i.e., sequencing by synthesis.


While single molecule techniques have several advantages, implementation has been problematic. For example, the reproducibility and accuracy of many single molecule techniques rely upon the stability of a primer/target nucleic acid duplex attached to a solid substrate. However, incomplete binding of the primer to the template, disengagement of the primer from the template and disengagement of the duplex from the substrate are frequent occurrences in such single molecule techniques.


Accordingly, there is a need in the art for methods and devices for sequencing generally, and single molecule sequencing in particular, including methods for stabilizing a target nucleic acid for sequence determination.


SUMMARY OF THE INVENTION

The invention generally provides methods and surfaces for nucleic acid sequencing comprising stabilized primer/target nucleic acid duplexes on a surface. Methods of the invention generally contemplate the use of a primer/target nucleic acid duplex in which each of the primer and the template contain a molecule having a binding partner on the substrate. The primer/target is stabilized on the surface by binding of both the primer and the template to the surface. Binding pairs for use in the invention are any molecular pair that can be bound to a surface and attached to a nucleic acid. Some examples of preferred pairs include ligand/receptor, affinity pairs, antigen/antibody, and carbohydrate/lectin. For example, biotin/streptavidin, digoxigenin/anti-digoxigenin, and dinitrophenol/anti-dinitrophenol perform well in the invention. Other pairs are apparent to the skilled artisan based upon the description of the invention provided below.


According to the invention, the primer contains a member of a binding pair at its 5′ terminus, and the template contains a member of a binding pair at its 3′ terminus or the primer contains a member of a binding pair at its 3′ terminus and the template contains a member of a binding pair at its 5′ terminus. Thus, the primer hybridizes to the template, and the two attached binding pair members are oriented to bind to their respective mates on the surface.


The template and primer may contain the same type or species of binding pair or they may contain separate types or species. Binding may occur to a single species of binding partner or to separate members of the same species. For example, in one embodiment, both the template and the primer are bioinylated at opposite ends oriented to the surface (i.e., one at the 3′ end and one at the 5′ end) and the two biotin molecules adhere to the same streptavidin molecule (which has capacity to bind four biotins) on the surface. Alternatively, the two biotins adhere to separate streptavidin molecules spaced closely together on the surface. In another embodiment, the primer is attached to a member of a first binding pair and the template is attached to a member of a second binding pair. Upon hybridization, the first member attaches to its mate on the surface, and the second member attaches to its separate mate on the surface. In either embodiment, the combination of two separate mating pairs reduces loss of the hybrid due to either the template or the primer dissociating. It is apparent to the skilled artisan based upon this disclosure that any combination of binding pairs works to stabilize hybrid binding to a surface. For example, template and primer may have attached separate species of binder that, although distinct, bind to the same surface-bound mate.


The invention comprises methods for sequencing nucleic acids using stabilized, support-bound primer/template hybrids as described above. In a preferred embodiment, methods of the invention comprise template-dependent sequencing by synthesis using a polymerase capable of adding nucleotides to the primer in a template-dependent fashion. The invention is particularly useful for single molecule nucleic acid sequencing in which primer/template duplex is attached to a substrate such that the duplex is individually optically resolvable. Individual strand sequence is determined by detecting ordered template-dependent nucleotide incorporation into the primer and compiling a sequence of the template based upon the order of incorporated nucleotides.


The invention also provides for the use of a stabilizing molecule in template-dependent sequencing. Stabilizing molecules useful in the invention include, for example, locked nucleic acid (“LNA”) analogs and peptide nucleic acid (“PNA”) analogs. Generally, a stabilizing molecule increases the affinity and specificity of the primer/target nucleic acid bond, and increases the melting temperature of the primer/target nucleic acid duplex or the specificity of incorporation of a nucleotide into the primer in a sequencing by synthesis reaction. An example of a locked nucleic acid is shown in FIG. 4. Both locked nucleic acid and peptide nucleic acid analogs increase the melting temperature of the primer/template duplex and, therefore, confer stability on the hybrid, whether or not the anchoring strategies described above are used.


Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer. Depending on the characteristics of the target nucleic acid, a DNA polymerase, an RNA polymerase, or a reverse transcriptase can be used. According to one aspect of the invention, a thermophilic polymerase is used, such as ThermoSequenase®, 9° N™, Taq, Tfl, Tth, Tli, Therminator, or Pfu. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius. A preferred polymerase is a Klenow fragment having reduced 3′-5′ exonuclease activity.


Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.


Nucleotides for primer addition according to the invention preferably comprise a detectable label. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.


In one embodiment, fluorescence resonance energy transfer (FRET) is used to determine the base type incorporated into the primer. Fluorescence resonance energy transfer in the context of sequencing is described generally in Braslavasky et al., Sequence Information can be Obtained from Single DNA Molecules, Proc. Nat'l Acad. Sci., 100: 3960–3964 (2003), incorporated by reference herein. Essentially, in one embodiment, a donor fluorophore is attached to either the primer, polymerase, or template. Nucleotides added for incorporation into the primer comprise an acceptor fluorophore that is activated by the donor when the two are in proximity. Activation of the acceptor causes it to emit a characteristic wavelength of light and also quenches the donor. In this way, incorporation of a nucleotide in the primer sequence is detected by detection of acceptor emission. Of course, nucleotides labeled with a donor fluorophore also are useful in methods of the invention; FRET-based methods of the invention only require that a donor and acceptor fluorophore pair are used, a labeled nucleotide may comprise one fluorophore and either the template or the polymerase may comprise the other. Such labeling techniques result in a coincident fluorescent emission of the labels of the nucleotide and the labeled template or polymerase, or alternatively, the fluorescent emission of only one of the labels.


In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.


Preferred substrates include glass, silica, and others with the optical properties described herein. Surfaces for sequencing according to the invention may be coated with, for example, an epoxide, polytetrafluoroethylene or a derivative of polytetrafluoroethylene, such as silanized polytetrafluoroethylene, a polyelectrolyte multilayer (PEM), or the equivalent.


Primers useful in the invention hybridize to template in a manner that allows template-dependent sequencing-by-synthesis. Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. The invention also teaches the use of stabilizing molecules used in connection with the primer or the primer/template duplex, such as locked nucleic acid or peptide nucleic acid analogs. According to the invention, the melting temperature of the primer/target nucleic acid duplex may be increased from about 3° to about 8° Celsius per PNA or LNA base included in the primer. In one embodiment, the primer comprises a locked nucleic acid base on its 3′ terminus. The primer may comprise any portion of PNA or LNA bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total nucleic acid residues in the primer. The PNA or LNA bases may be consecutive in the primer or may be interspersed throughout the primer. In a preferred embodiment, PNA or LNA bases are spaced apart at a distance of at least one turn of the helix when the primer is hybridized to template. The use of LNA or PNA analogs allows primers to be shorter than would be the case to achieve similar melting temperatures using conventional nucleic acids. According to one embodiment of the invention, the primer comprises fewer than 25 nucleic acids.


Methods of the invention are suitable for de novo sequencing, re-sequencing, sequence analysis, DNA fingerprinting, polymorphism identification, for example single nucleotide polymorphisms (SNP) detection, as well as for research and clinical applications in genetics. Applied to RNA sequences, methods according to the invention also identify alternate splice sites, enumerate copy number, measure gene expression, identify unknown RNA molecules present in cells at low copy number, annotate genomes by determining which sequences are actually transcribed, determine phylogenic relationships, and elucidate differentiation of cells. Methods and surfaces of the invention are useful in diagnostic, therapeutic, prognostic (including drug selection), and developmental applications.


As will be appreciated by one skilled in the art, individual features of the invention may be used separately or in any combination. A detailed description of embodiments of the invention is provided below. Other embodiments of the invention are apparent upon review of the detailed description that follows.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts a dual biotinylation reaction securing a primer and target nucleic acid to a substrate.



FIG. 2 depicts a primer (SEQ ID NO: 4) and target nucleic acid (SEQ ID NO: 3) biotinylated to align complementary nucleotides.



FIG. 3 depicts three primers (SEQ ID NOS 5–7, respectively in order of appearance) comprising locked nucleic acid bases.



FIG. 4 depicts the structure of a locked nucleic acid base.



FIG. 5 shows the relative stability of dual biotin duplex on a streptavidinated PEM.





DETAILED DESCRIPTION

The results of single molecule sequencing are influenced by the stability of substrate-bound primer/target nucleic acid duplexes. Typically, single molecule sequencing comprises repeated single base extension reactions followed by one or more wash steps. Sequencing occurs on single strands spaced apart such that each strand is individually optically resolvable. Spatial and temporal stability of the individual strands are important in order to preserve the integrity of the sequencing process. One way in which the spatial stability of a single molecule array can be disrupted is if the template and/or primer become disassociated with the surface. For example, template/primer hybridization is a dynamic process. Primer melts off template at a low, but detectable rate. Once melting occurs, at least some portion of primer will be unavailable to re-anneal with template. That is not necessarily a problem in a bulk sequencing reaction in which numerous copies of each template are available for sequencing. However, in single molecule sequencing, in which individual strands are sequenced, loss of any strand can have a significant effect on the result. Methods and surfaces of the invention address this problem by placing stabilizing binding partners on each of the template and primer and, optionally, utilizing stabilizing molecules that confer an increased melting temperature on the primer/template hybrid.


I. General Considerations


Substrates


Generally, a substrate may be made of any suitable material that allows single molecules to be individually optically resolvable. Substrates for use according to the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped. Appropriate substrates include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silica, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.


Preferably, a substrate used according to the invention includes a biocompatible or biologically inert material that is transparent to light and optically that (i.e., with a minimal micro-roughness rating). Specially manufactured, or chemically derivatized, low background fluorescence substrates (e.g., glass slides) are also contemplated according to the invention. Substrates may be prepared and analyzed on either the top or bottom surface of the planar substrate (i.e., relative to the orientation of the substrate in the detection system).


The invention also includes three-dimensional substrates such as spheres, tubes (e.g., capillary tubes), microwells, microfluidic devices, or any other structure suitable for anchoring a nucleic acid. For example, a substrate can be a microparticle, a bead, a membrane, a slide, a plate, a micromachined chip, and the like. Substrates can include planar arrays or matrices capable of having regions that include populations of target nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol; and the like.


Factors for selecting substrates include, for example, the material, porosity, size, and shape. Other important factors to be considered in selecting appropriate substrates include size uniformity, efficiency as a synthesis support, and the substrate's optical properties, e.g., clear smooth substrates (free from defects) provide instrumentational advantages when detecting incorporation of nucleotides in single molecules (e.g., nucleic acids.).


Substrates are coated with a surface that facilitates nucleic acid binding and that reduces background. Preferred coatings are epoxides, silanized epoxides, biotinylated epoxides, streptavidinated epoxides, polyelecrolyte multilayers, including those that are derivatized for nucleic acid attachment (e.g., biotinylated, streptavidinated, or coated with a binding partner on the template/primer.


Surfaces


Surfaces used to attach duplexes according to the invention can be any surface to which a binding partner is capable of attaching. For sequencing, surfaces should be free of debris, especially debris capable of fluorescing. Also, surfaces should be stable and transparent to light. Preferred surfaces are epoxy surfaces and polyelectrolyte multilayer surfaces. Either of those surfaces is easily derivatized as described in the art for attachment of binding pairs. For example, epoxide surfaces are derivatized with silane or other species capable of receiving binding partners. In certain embodiments, binding pair members attached to template/primer hybrids attach directly to the surface via a molecule embedded in the surface that is not the normal binding partner for the binding pair member. Polyelectrolyte multilayer surfaces are formed from a variety of alternating layers of positive and negative charge. Preferred polyelectrolyte multilayer surfaces are described in detail below.


Target Nucleic Acids


A target nucleic acid for analysis may be obtained from a patient sample, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, breast nipple aspirate, sputum, stool and biopsy tissue. Any tissue or body fluid specimen may be used according to methods of the invention.


A target nucleic acid can come from a variety of sources. For example, nucleic acids can be naturally occurring DNA or RNA isolated from any source, recombinant molecules, cDNA, or synthetic analogs, as known in the art. For example, the target nucleic acid may be genomic DNA, genes, gene fragments, exons, introns, regulatory elements (such as promoters, enhancers, initiation and termination regions, expression regulatory factors, expression controls, and other control regions), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, and other mutations. Also included is the full genome of one or more cells, for example cells from different stages of diseases such as cancer. The target nucleic acid may also be mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, or siRNA. Also contemplated according to the invention are RNA with a recognition site for binding a polymerase, transcripts of a single cell, organelle or microorganism, and all or portions of RNA complements of one or more cells, for example, cells from different stages of development or differentiation, and cells from different species. Nucleic acids can be obtained from any cell of a person, animal, plant, bacteria, or virus, including pathogenic microbes or other cellular organisms. Individual nucleic acids can be isolated for analysis.


Stabilizing Molecules and Primers


Methods of the invention also contemplate using a stabilizing molecule in a sequencing-by-synthesis reaction. The stabilizing molecule strengthens the primer/template bond and increases the specificity of incorporation of nucleotides into the primer, the melting temperature of the primer/target nucleic acid duplex, or both. A stabilizing molecule may comprise nucleotide or internucleotide analogs, or covalently bound minor groove binders or intercalators that enhance hybridization avidity or specificity of the primer to a target nucleic acid. The internucleotide analogs can comprise one or more of a phosphate ester analog such as alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates and phosphorodithioates.


In one aspect, the stabilizing molecule comprises a minor groove binder. Minor groove binders are described in detail in U.S. Pat. No. 6,084,102 which is incorporated by reference in its entirety herein. Generally, a minor groove binder has a molecular weight of approximately 150 to approximately 2000 daltons, and typically covalently attaches to at least one of the nucleotides in a duplex. It incorporates into a duplex to strengthen the template/primer bond, thus increasing hybridization stability.


In one embodiment, a stabilizing molecule may comprise a conformationally restricted nucleotide analog such as a peptide nucleic acid base, a locked nucleic acid base or an oxetane modified base (for a discussion of base constraining oxetane modifications, see U.S. Published Patent Application No. 20040142946, the disclosure of which is incorporated by reference herein). A peptide nucleic acid is a nucleic acid analog in which the backbone comprises synthetic peptide like linkages (amide bonds) usually formed from N-(2-amino-ethyl)-glycine units, resulting in an achiral and uncharged molecule. PNA hybridizes with complementary nucleic acids with high affinity and specificity, and forms PNA/DNA and PNA/RNA duplexes having greater thermal and chemical stability than counterpart DNA/DNA duplexes.


A locked nucleic acid is a bicyclic nucleic acid analog that contains one or more 2′-O, 4′-C methylene linkage(s), which effectively locks the furanose ring in a C3′-endo conformation. This methylene linkage “bridge” restricts the flexibility of the ribofuranose ring and locks the structure into a rigid bicyclic formation. Because of its unique structural conformation, locked nucleic acids demonstrate a much greater affinity and specificity to their complementary nucleic acids than do natural DNA counterparts and increases the thermal and chemical stability of a primer/target nucleic acid duplex. LNAs will hybridize to complementary nucleic acids even under adverse conditions, such as under low salt concentrations and in the presence of chaotropic agents. According to one aspect of the invention, locked nucleic acids increase the melting point of the primer/target nucleic acid duplex by about 3° to about 8° Celsius per locked nucleic acid base incorporated in the primer. FIG. 4 shows an example of the structure of a locked nucleic acid base.


Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. Locked nucleic acid bases may be interspersed throughout a strand of a primer, as shown in FIG. 3, or may be placed consecutively or singularly in predetermined locations. The amount and placement of the locked nucleic acid bases depends on the desired characteristics of the primer. In one embodiment, the primer comprises a locked nucleic acid base at its 3′ terminus. The primer may comprise any portion of locked nucleic acid bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total bases in the primer.


In general, primer length is selected to facilitate hybridization to a sufficiently complementary region of the template nucleic acid downstream of the region to be analyzed. The exact lengths of the primers depend on many factors, including temperature and source of primer. Placement of locked nucleic acid bases throughout a primer allows for an increased melting temperature of the primer/target nucleic acid duplex during a sequencing reaction. This also allows the primer length to remain short compared to a primer that does not contain locked nucleic acid bases. Embodiments of this invention include primers with 20 bases or less, which incorporate from 1 to 12 or more locked nucleic acid bases. For example, a 20 base primer which includes 12 locked nucleic acid bases may yield a melting temperature of between about 80° to 90° C. According to one embodiment of the invention, the primer comprises less than about 30, 25, 20, 15, 10, or 5 bases.



FIG. 3 shows three exemplary primers (DXS17, 7G7A, and 377), each containing nine locked nucleic acids and comprising a sequence complementary to a known primer attachment site of a target nucleic acid. While FIG. 3 shows primers of known sequences complementary to a known region of a template, primers useful in the invention also include primers comprising a random sequences. Useful primers also include primers comprising a sequence that is complementary to a known priming region that has been ligated to a target nucleic acid.


Primers can be synthetically made using conventional nucleic acid synthesis techniques. For example, primers are synthesized on an automated DNA synthesizer (e.g., Applied Biosystems, Inc., Foster City, Calif.) using standard chemistries, such as phosphoramidite chemistry, and the like. Alternative chemistries, e.g., resulting in non-natural backbone groups, such as phosphorothioate, phosphoramidate, and the like, may also be employed provided that, for example, the resulting oligonucleotides are compatible with the polymerizing agent. The primers can also be ordered commercially from a variety of companies which specialize in custom nucleic acids such as Operon, Inc. (Alameda, Calif.). Primers comprising locked nucleic acids are purchased commercially (Proligo® LLC, Boulder, Colo.) or prepared as needed by methods known in the art.


The foregoing methods confer a significant advantage in single molecule reactions, in which one is tracking nucleotide incorporation into individual template/primer duplexes. Single molecule techniques provide the ability to observe discrete differences within and between individuals in terms of nucleotide sequence. Disruption of a hybrid impairs the ability to obtain full advantage from single molecule techniques because the loss of a hybrid represents the loss of significant information content relative to a bulk reaction in which there exist numerous copies of each hybrid pair. Methods of the invention maximize the ability to keep hybrid pairs intact and attached to substrate.


Primer Hybridization


Conditions for hybridizing primers to target nucleic acids are known in the art. The annealing reaction is performed under conditions which are stringent enough to ensure sequence specificity, yet sufficiently permissive to allow formation of stable hybrids at an acceptable rate. The temperature and length of time required for primer annealing depend upon several factors including the base composition, length and concentration of the primer, and the nature of the solvent used, e.g., the concentration of cosolvents such as DMSO (dimethylsulfoxide), formamide, or glycerol, and counterions such as magnesium. Typically, hybridization (annealing) is carried out at a temperature that is approximately 5 to 10° Celsius below the melting temperature of the primer/target nucleic acid duplex in the annealing solvent. Annealing temperatures may be modified based on the amount of locked nucleic acid included in the primer, based on manufacturer's recommendation and methods known in the art.


Primer Extension and Labeling


During primer extension, the primer/target nucleic acid duplex is exposed to a polymerase, and at least one nucleotide or nucleotide analog under conditions that allow for incorporation of the nucleotide into the primer. Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependant addition of a nucleotide to a primer, such as, Klenow, Vent ThermoSequenase®, 9° N™, Therminator, Taq, Tfl, Tth, Tli, Pfu, and others. According to one aspect of the invention, a thermophilic polymerase is used. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius, or at least about 50°, 60°, or 70° Celsius.


Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids, oxetane-modified bases and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.


Nucleotides particularly useful in the invention comprise detectable labels. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.


Other suitable fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); 5′5″-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC); eosin and derivatives; eosin, eosin isothiocyanate, erythrosin and derivatives; erythrosin B, erythrosin, isothiocyanate; ethidium; fluorescein derivatives; 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2′,7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives: pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum dots; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A) rhodamine and derivatives: 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine; tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid; terbium chelate derivatives; Cy5.5; Cy7; IRD 700; IRD 800; La Jolta Blue; phthalo cyanine; and naphthalo cyanine.


In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.


Further, the primer or the target nucleic acid can also include a detectable label. When the labeled primer and/or target nucleic acid are attached to the substrate, the label facilitates locating the bound molecule through imaging. The primer or target nucleic acid can be labeled with a fluorescent labeling moiety (e.g., Cy3 or Cy5), or any other means used to label nucleotides. The detectable label used to label the primer or target nucleic acid can be different from the label used on the nucleotides or nucleotide analogs in the subsequent extension reactions. Additionally, once the molecule has been localized, it may be desirable to render the label undetectable prior to the nucleotide incorporation detection steps by methods such as washing or photobleaching.


A nucleotide analog according to the invention can be modified to remove, cap or modify the 3′ hydroxyl group. As such, in certain embodiments, methods of the invention can include, for example, the step of removing the 3′ hydroxyl group from the incorporated nucleotide or nucleotide analog. By removing the 3′ hydroxyl group from the incorporated nucleotide in the primer, further extension is halted or impeded. In certain embodiments, the modified nucleotide can be engineered so that the 3′ hydroxyl group can be removed and/or added by chemical methods. Alternatively, a nucleotide analog can be modified to include a moiety that is sufficiently large to prevent or sterically hinder further chain elongation by interfering with the polymerase, thereby halting incorporation of additional nucleotides or nucleotide analogs. Subsequent removal of the moiety, or at least the steric-hindering portion of the moiety, can concomitantly reverse chain termination and allow chain elongation to proceed. In some embodiments, the moiety also can be a label. As such, in those embodiments, chemically cleaving or photocleaving the blocking moiety may also chemically-bleach or photobleach the label, respectively.


Detection of Incorporated Nucleotides


Incorporation of a nucleotide or a nucleotide analog and their locations on the surface of a substrate can be detected with single molecule sensitivity according to the invention. In some aspects of the invention, single molecule resolution is achieved by anchoring a target nucleic acid at a low concentration to a substrate, and then imaging nucleotide incorporation with for example, with total internal reflection fluorescence microscopy.


A number of detection methods are available for use in single molecule analysis. Methods for visualizing single molecules within nucleic acids labeled with an intercalating dye include, for example, fluorescence microscopy. For example, the fluorescent spectrum and lifetime of a single molecule excited-state can be measured. Standard detectors such as a photomultiplier tube or avalanche photodiode can be used. Full field imaging with a two-stage image intensified COD camera also can be used. Additionally, low noise cooled CCD can also be used to detect single fluorescent molecules.


The detection system for the signal may depend upon the labeling moiety used, which can be defined by the chemistry available. For optical signals, a combination of an optical fiber or CCD can be used in the detection step. In the embodiments where the substrate is itself transparent to the radiation used, it is possible to have an incident light beam pass through the substrate with the detector located opposite the substrate from the primer. For electromagnetic labels, various forms of spectroscopy systems can be used. Various physical orientations for the detection system are available and known in the art.


A number of approaches can be used to detect incorporation of fluorescently-labeled nucleotides into a single molecule. Optical systems include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy. In general, methods involve detection of laser-activated fluorescence using a microscope equipped with a camera, sometimes referred to as high-efficiency photon detection system. Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras. For example, as illustrated in FIG. 2, an intensified charge couple device (ICCD) camera can be used. The use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.


Certain embodiments of the invention are described in the following examples, which are not meant to be limiting.


II. EXAMPLES
Example 1
Dual Biotinylation

General methods of the invention were demonstrated using biotin/avidin binding pairs. When a biotin-streptavidin linkage is used to anchor a primer and a target nucleic acid to a substrate, the primer and target nucleic acid are biotinylated, while the surface of the substrate is coated with streptavidin. Because streptavidin is a tetramer, it is possible that both template and primer will bind to the same surface streptavidin. However, the dual biotin labels may bind to adjacent streptavidin molecules as well.


Two experiments were done to determine the binding stability of the dual biotin constructs. A first experiment was conducted in order to determine the stability of dual biotin duplex on a polyelectrolyte multilayer (PEM) surface. This experiment was done using covalent streptavidin attachment to a PEM surface. The PEM surfaces were prepared as follows. Polyethyleneimine (PEI) and pollyallylamine (PAA, Sigma, St. Louis, Mo.) were dissolved separately by stirring in MilliQ water and the pH was adjusted to 8.0 with dilute HCl. The solutions were filtered using a 0.22μ filter flask and stored at 4° C. Clean glass slides were then alternatively immersed for 10 minutes in the PEI and PAA solutions four times each with an 8 minute rinse using MilliQ water between each immersion. After the last rinse, the slides were kept immersed in water. The slides were then transferred to MES buffer (2-[N-morpholino] ethanesulfonic acid), pH 5.5 for EDC-induced crosslinking of the PEM. A 10 mM solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) was prepared in MES buffer, filtered and added to the solution containing the PEM-coated slides for 1 hour at room temperature. Slides were then rinsed in MES buffer and stored.


Next, the PEM surfaces were amine-derivatized by treatment with 10 mM NHS and 10 mM EDC in 0.1 M MES buffer, pH 6.0, OSM NaCl (coupling buffer) for 15 minutes. The surfaces were then rinsed twice in the coupling buffer and incubated for 1 hour in 0.1 mg/ml Streptavidin Plus (SA-20, Prozyme) in the coupling buffer. The resulting streptavidinated surfaces were rinsed in a 200 μl solution of dual-biotin duplex in which the primer had the sequence: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1) and the template had the sequence: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2; primer binding region bolded and underlined). At its 3′ end, the terminal thymidine was labeled with cyanine-5 dye and the adenine two positions 5′ of the terminus was labeled with a cyanine-3 dye. Surfaces were soaked for 5 minutes and then rinsed once in 20 mM Tris, pH 8.0, 50 mM NaCl, 0.01% Triton (Rinse Buffer). The surfaces were then rinsed 5 times in 3×SSC-0.1% Triton, with a 10 minute soak in the last rinse. Finally, the surfaces were rinsed in two changes of the Rinse Buffer. The resulting surface had dual-biotin primer/target nucleic acid duplex bound to streptavidin. A second set of slides was rinsed with the dual biotin duplexes as described above, but was also challenged with 100 nM unlabeled biotin. All slides were imaged over a 1000 μ2 area and analyzed in ImagePro (Media Cybernetics, San Diego) using a dark image background subtraction algorithm.


Visualization of surface-bound duplexes was accomplished using fluorescence resonance energy transfer (FRET), with the cyanine-5 labeled thymidine as the donor and the cyanine-3 labeled adenine as the acceptor. Slides were placed on a Nikon Eclipse TE-2000 inverted microscope with a total internal reflection objective. The dual-biotin duplex slides showed 309.7 counts/pixel and the biotin-challenged slides showed 10.1 counts/pixel. These results indicate that the dual-biotin duplexes were binding to streptavidin on the PEM in a specific manner, as the cold biotin was able to compete away duplex binding.


In a separate experiment, the dual biotin duplexes referred to above were first bound to a streptavidinated PEM surface as described above. The surface was then exposed to 100 nM unlabeled biotin at 52° C. for 10 minutes. As a control, streptavidinated PEMs were incubated in parallel and then rinsed with dual-biotin duplex. All slides then were washed, imaged, and analyzed as described above. The data are shown in FIG. 5. The results indicate that the dual-biotin duplexes on a streptavidinated PEM surface are surface-stable.


Another experiment shows the stability of dual-biotin duplexes in single molecule sequencing. For this experiment, streptavidinated slides are prepared on a PEM as described above. The slides then are biotinylated. Fresh biotin-long chain polyethyloxide-amine (Biotin-LC-PEO, Pierce) is prepared in MES buffer (50 mg Biotin in 2.5 ml MES). A 5 ml aliquot of the EDC solution described above is combined with 5 ml of the Biotin-LC-PEO solution and diluted in MES buffer to a total volume of 96 ml by adding 86 ml of MES buffer to a 2.5 mM final EDC-biotin concentration. The PEM-coated slides are then immersed in that solution in a 100 ml beaker and incubated for 60 minutes at room temperature. The slides are then rinsed in MES buffer with gentle agitation for 10 seconds. Immersion and rinsing are repeated four times in clean 100 ml volumes. Slides are then incubated in the final bath for 10 minutes. The resulting biotin-coated slides are stored in Tris-NaCl buffer prior to streptavidination.


Streptavidin-Plus (SA20, Prozyme) is dissolved in a solution of 10 mM NaCl buffer at 0.14 mg/ml and stirred 10 minutes at room temperature to thoroughly dissolve flakes. The resulting solution is filtered with a 0.22μ filter. Biotinylated slides described above are placed in this solution in a 100 ml beaker with a stir bar and stirred for 15 minutes at room temperature. The slides are then rinsed in 100 ml Tris-NaCl buffer with gentle agitation for 10 seconds. The rinse process is repeated 5 times in clean 100 ml volumes of 3×SSC-0.1% Triton, incubating in the final bath for 10 minutes. Finally, the slides are transferred to a fresh bath of Tris-NaCl and agitated for 10 seconds. Slides arestored in Tris-NaCl buffer at 4° C. prior to use.


3′ bioinylated target nucleic acid templates: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2), are obtained from Integrated DNA Technologies (Coral, IA). 5′ biotinylated primers: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1), comprising a cyanine-5 dye were hybridized to the templates and exposed to the streptavidinated surfaces described above at a concentration of 10 pM. After incubation for 10 minutes, the surfaces are washed with MES buffer and the surface was imaged using a Nikon TE-2000U upright microscope equipped with a total internal reflection objective (Nikon). The location of label represented the location of bound hybrid and the positions of label are noted. Positional detection can also be accomplished using unlabeled template/primer and adding labeled first base. To determine the stability of bound duplexes, nucleotide additions are accomplished using the Klenow fragment (exo-) polymerase (New England Biolabs) at 10 mM in Ecopol reaction buffer and a series of cyanine-labeled nucleotide triphosphates. To reduce bleaching of the fluorescent dyes, an oxygen scavenging system is used (glucose (0.36%), glucose oxidase (8 U/ml), catalase (423 U/ml), Trolox (5 mM), Gallate (5 mM), DABCO (10 mM), and 2,4,6-octatrienoic acid).


The positions of cyanine-5-labeled primer are recorded and bleached. dUTP-Cy3 in polymerase is added to the slides. If dUTP is incorporated into the primer, fluorescence resonance energy transfer (FRET) from the cyanine-5 on the primer will caus the cyanine-3 dye to emit and the location of the emission is detected. The cyanine-3 dye is kept unbleached and subsequent additions are with cyanine-5-labeled dNTPs, using FRET with cyanine-3 as the donor for detection of incorporation. The results show that dual-biotin duplex is a stable template for template-dependent sequencing.


The skilled artisan understands that there are numerous other embodiments of the invention in terms of surfaces, binding partners and the like that can be manipulated in order to achieve the stability results shown above.


Example 2
Locked Nucleic Acid

A primer is designed to be complementary to a known primer attachment site of the target nucleic acid, and locked nucleic acid bases are substituted for certain nucleotides within the selected primer sequence. As many locked nucleic acid bases are selected as desired depending on the temperature and length of primer, up to a primer comprising 100% locked nucleic acids. The more locked nucleic acid substitutions into the primer, the greater the melting point of the primer/target nucleic acid duplex relative a primer of the same length lacking locked nucleic acid residues.



FIG. 3 shows three primers synthesized with locked nucleic acids. DXS17, 7G7A, and 377 primers were synthesized as complementary strands to known regions of a template, each primer incorporating nine locked nucleic acids. When these primers are annealed to their respective templates, hybridization may be carried out at temperatures between about 80° C. to about 90° C.


The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims
  • 1. A method for stabilizing a nucleic acid duplex on a surface, the method comprising the steps of: contacting a surface with a nucleic acid duplex comprising a first and a second nucleic acid member, wherein each nucleic acid member comprises a binding pair member and at least one of said nucleic acid members comprises a binding pair member at its 3′ terminus, wherein the surface comprises a binding partner for each of said binding pair members, and wherein said binding pair is a carbohydrate/lectin pair or an antigen/antibody pair,
  • 2. The method of claim 1, wherein each of said binding pair members is the same molecular species.
  • 3. The method of claim 1, wherein each said member of said binding pair is a different molecular species.
  • 4. The method of claim 1, wherein said binding pair is selected from the group consisting or biotin/avidin, biotin/streptavidin, digoxigenin/anti-digoxigenin, and dinitrophenol/anti-dinitrophenol.
  • 5. The method of claim 1, wherein said nucleic acid duplex is a template/primer duplex.
  • 6. The method of claim 1, wherein each of said binding pair members is located at the 5′ terminus of said template and the 3′ terminus of said primer.
  • 7. The method of claim 1, wherein one of said binding pair members is located at the 5′ terminus of said primer.
  • 8. The method of claim 5, further comprising the steps of contacting a surface-bound nucleic acid duplex to a nucleotide base and a polymerase under conditions sufficient for said nucleotide base to be incorporated into said primer if said nucleotide base is complementary to a corresponding base in said template.
  • 9. The method of claim 8, further comprising the step of compiling a nucleic acid sequence of said template by detecting sequential incorporations of nucleotides into said primer.
  • 10. The method of claim 5, wherein said primer comprises a locked nucleic acid base.
  • 11. The method of claim 5, wherein said primer comprises a peptide nucleic acid base.
  • 12. A method for performing a nucleic acid sequencing reaction, the method comprising: contacting a mixture comprising a nucleic acid template, a polymerase, and a primer, wherein said primer comprises a locked nucleic acid, with a nucleotide under conditions wherein said nucleotide is capable of incorporation into said primer, wherein said nucleic acid template and said primer each comprises a binding pair member, and wherein said template and said primer form a stabilized nucleic acid duplex on a surface, the surface comprising a binding partner for each said binding pair member, and wherein said binding pair is a carbohydrate/lectin pair or an antigen/antibody pair,
  • 13. The method of claim 1, wherein a plurality of said nucleic acid duplexes is attached to a substrate such that each of said nucleic acid duplexes is individually optically resolvable.
  • 14. The method of claim 12, further comprising detecting ordered template-dependent nucleotide incorporation into the primer and compiling a sequence of the template based upon the order or incorporated nucleotides.
US Referenced Citations (437)
Number Name Date Kind
3996345 Ullman et al. Dec 1976 A
4119368 Yamazaki Oct 1978 A
4153855 Feingold May 1979 A
4344064 Bitler et al. Aug 1982 A
4351760 Khanna et al. Sep 1982 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4707237 Lepp et al. Nov 1987 A
4711955 Ward et al. Dec 1987 A
4725677 Kosler et al. Feb 1988 A
4739044 Slabinskv Apr 1988 A
4757141 Fung et al. Jul 1988 A
4793705 Shera Dec 1988 A
4811218 Hunkapiller et al. Mar 1989 A
4863849 Melamede Sep 1989 A
4865968 Orgel et al. Sep 1989 A
4889818 Gelfand et al. Dec 1989 A
4942124 Church Jul 1990 A
4962037 Jett et al. Oct 1990 A
4971903 Hyman Nov 1990 A
4979824 Mathies et al. Dec 1990 A
4994368 Goodman et al. Feb 1991 A
4994372 Tabor et al. Feb 1991 A
4994373 Stavrianopoulos et al. Feb 1991 A
5085562 Van Lintel Feb 1992 A
5091652 Mathies et al. Feb 1992 A
5096388 Weinberg Mar 1992 A
5096554 Chin et al. Mar 1992 A
5108892 Burke et al. Apr 1992 A
5112736 Caldwell et al. May 1992 A
RE34069 Koster et al. Sep 1992 E
5143854 Pirrung et al. Sep 1992 A
5167784 Noolandi Dec 1992 A
5171132 Miyazaki et al. Dec 1992 A
5198540 Koster Mar 1993 A
5209834 Shera May 1993 A
5224843 Van Lintel Jul 1993 A
5242796 Prober et al. Sep 1993 A
5242797 Hirschfeld Sep 1993 A
5258506 Urdea et al. Nov 1993 A
5259737 Kamisuki et al. Nov 1993 A
5260433 Engelhardt et al. Nov 1993 A
5265327 Faris et al. Nov 1993 A
5267152 Yang et al. Nov 1993 A
5302509 Cheeseman Apr 1994 A
5304487 Wilding et al. Apr 1994 A
5306403 Vo-Dinh Apr 1994 A
5336062 Richter Aug 1994 A
5360523 Middendorf et al. Nov 1994 A
5375979 Trah Dec 1994 A
5376252 Ekstrom et al. Dec 1994 A
5403709 Agrawal et al. Apr 1995 A
5405747 Jett et al. Apr 1995 A
5405783 Pirrung et al. Apr 1995 A
5409811 Tabor et al. Apr 1995 A
5424186 Fodor et al. Jun 1995 A
5436149 Barnes Jul 1995 A
5449767 Ward et al. Sep 1995 A
5476928 Ward et al. Dec 1995 A
5484701 Cocuzza et al. Jan 1996 A
5492806 Drmanac et al. Feb 1996 A
5514256 Douthart et al. May 1996 A
5518900 Nikiforov et al. May 1996 A
5525464 Drmanac et al. Jun 1996 A
5529465 Zengerle et al. Jun 1996 A
5534125 Middendorf et al. Jul 1996 A
5547839 Dower et al. Aug 1996 A
5547859 Goodman et al. Aug 1996 A
5556790 Pettit Sep 1996 A
5558991 Trainor Sep 1996 A
5599695 Pease et al. Feb 1997 A
5610287 Nikiforov et al. Mar 1997 A
5631734 Stern et al. May 1997 A
5632957 Heller et al. May 1997 A
5654149 Mendoza et al. Aug 1997 A
5659171 Young et al. Aug 1997 A
5670346 Reeve et al. Sep 1997 A
5674716 Tabor et al. Oct 1997 A
5675155 Pentoney, Jr. et al. Oct 1997 A
5688648 Mathies et al. Nov 1997 A
5695940 Drmanac et al. Dec 1997 A
5705018 Hartley Jan 1998 A
5707506 Douthart et al. Jan 1998 A
5710628 Waterhouse et al. Jan 1998 A
5712476 Renfrew et al. Jan 1998 A
5733729 Lipshutz et al. Mar 1998 A
5741640 FuBer Apr 1998 A
5741644 Kambara et al. Apr 1998 A
5744305 Fodor et al. Apr 1998 A
5744312 Mamone et al. Apr 1998 A
5750341 Macevicz et al. May 1998 A
5753788 Fodor et al. May 1998 A
5755943 Middendorf et al. May 1998 A
5756285 Fuller May 1998 A
5759014 Van Lintel Jun 1998 A
5759374 Takahashi et al. Jun 1998 A
5762876 Lincoln et al. Jun 1998 A
5763594 Hiatt et al. Jun 1998 A
5776767 Stevens et al. Jul 1998 A
5776782 Tsuji Jul 1998 A
5789168 Leushner et al. Aug 1998 A
5795722 Lacroix et al. Aug 1998 A
5795782 Church et al. Aug 1998 A
5807679 Kamb Sep 1998 A
5808045 Hiatt et al. Sep 1998 A
5830657 Leushner et al. Nov 1998 A
5831070 Pease et al. Nov 1998 A
5832165 Reichert et al. Nov 1998 A
5834758 Trulson et al. Nov 1998 A
5836750 Cabuz Nov 1998 A
5837832 Chee et al. Nov 1998 A
5837860 Anderson et al. Nov 1998 A
5846396 Zanzucchi et al. Dec 1998 A
5846727 Soper et al. Dec 1998 A
5853979 Green et al. Dec 1998 A
5858671 Jones Jan 1999 A
5861287 Metzker et al. Jan 1999 A
5863722 Brenner Jan 1999 A
5872244 Hiatt et al. Feb 1999 A
5876187 Afomowitz Mar 1999 A
5876934 Duthie et al. Mar 1999 A
5882904 Riedl et al. Mar 1999 A
5885813 Davis et al. Mar 1999 A
5889165 Fodor et al. Mar 1999 A
5902723 Dower et al. May 1999 A
5908755 Kumar et al. Jun 1999 A
5916747 Gilchrist et al. Jun 1999 A
5922591 Anderson et al. Jul 1999 A
5922608 Farnsworth et al. Jul 1999 A
5928906 Koster et al. Jul 1999 A
5928919 Reha-Krantz et al. Jul 1999 A
5945283 Kwok et al. Aug 1999 A
5945284 Livak et al. Aug 1999 A
5945312 Goodman et al. Aug 1999 A
5945325 Arnold et al. Aug 1999 A
5948614 Chatterjee Sep 1999 A
5952174 Nikiforov et al. Sep 1999 A
5954932 Takahashi et al. Sep 1999 A
5958703 Dower et al. Sep 1999 A
5959781 Kintz et al. Sep 1999 A
5959837 Yu Sep 1999 A
5965446 Ishikawa Oct 1999 A
5968740 Fodor et al. Oct 1999 A
5974164 Chee Oct 1999 A
5976338 Fujita et al. Nov 1999 A
5981186 Gabe et al. Nov 1999 A
5981956 Stern Nov 1999 A
5994058 Senapathy Nov 1999 A
5994085 Cantor Nov 1999 A
6002471 Quake Dec 1999 A
6005663 Waterhouse et al. Dec 1999 A
6007309 Hartley Dec 1999 A
6015714 Baldarelli et al. Jan 2000 A
6017702 Lee et al. Jan 2000 A
6018041 Drmanac et al. Jan 2000 A
6020457 Klimash et al. Feb 2000 A
6024925 Little et al. Feb 2000 A
6025136 Drmanac Feb 2000 A
6028190 Mathies et al. Feb 2000 A
6030782 Anderson et al. Feb 2000 A
6043080 Lipshutz et al. Mar 2000 A
6046005 Ju et al. Apr 2000 A
6049380 Goodwin et al. Apr 2000 A
6051380 Sosnowski et al. Apr 2000 A
6066454 Lipshutz et al. May 2000 A
6071394 Cheng et al. Jun 2000 A
6077664 Slater et al. Jun 2000 A
6077674 Schleifer et al. Jun 2000 A
6087095 Rosenthal et al. Jul 2000 A
6087099 Gupte et al. Jul 2000 A
6094274 Yokoi Jul 2000 A
6107032 Kilger et al. Aug 2000 A
6107044 Nikiforov Aug 2000 A
6107061 Johnson Aug 2000 A
6132580 Mathies et al. Oct 2000 A
6133436 Koster et al. Oct 2000 A
6136212 Mastrangelo et al. Oct 2000 A
6136962 Shi et al. Oct 2000 A
6140053 Koster Oct 2000 A
6140494 Hamilton et al. Oct 2000 A
6141096 Stern et al. Oct 2000 A
6143151 Middendorf et al. Nov 2000 A
6147205 McGall et al. Nov 2000 A
6156501 McGall et al. Dec 2000 A
6165694 Liu Dec 2000 A
6177249 Kwok et al. Jan 2001 B1
6197506 Fodor et al. Mar 2001 B1
6197595 Anderson et al. Mar 2001 B1
6207381 Larsson et al. Mar 2001 B1
6207960 Stern Mar 2001 B1
6210896 Chan Apr 2001 B1
6214246 Craighead Apr 2001 B1
6214987 Hiatt et al. Apr 2001 B1
6221592 Schwartz et al. Apr 2001 B1
6221654 Quake et al. Apr 2001 B1
6225052 Batz et al. May 2001 B1
6225062 Dunn et al. May 2001 B1
6225092 Kilger et al. May 2001 B1
6225109 Juncosa et al. May 2001 B1
6225567 Kester May 2001 B1
6225625 Pirrung et al. May 2001 B1
6228593 Lipshutz et al. May 2001 B1
6232075 Williams May 2001 B1
6232103 Short May 2001 B1
6235465 Kolberg et al. May 2001 B1
6235473 Friedman et al. May 2001 B1
6242180 Chee Jun 2001 B1
6242528 Clark et al. Jun 2001 B1
6245506 Laugharn, Jr. et al. Jun 2001 B1
6245507 Bogdanov Jun 2001 B1
6245518 Baier Jun 2001 B1
6251610 Gupte et al. Jun 2001 B1
6255083 Williams Jul 2001 B1
6255475 Kwiatkowski Jul 2001 B1
6258533 Jones Jul 2001 B1
6261775 Bastian et al. Jul 2001 B1
6261776 Pirrung et al. Jul 2001 B1
6261848 Anderson et al. Jul 2001 B1
6262838 Montagu Jul 2001 B1
6263286 Gilmanshin et al. Jul 2001 B1
6268152 Fodor et al. Jul 2001 B1
6268219 Mcbride et al. Jul 2001 B1
6269846 Overbeck et al. Aug 2001 B1
6270644 Mathies et al. Aug 2001 B1
6270961 Drmanac Aug 2001 B1
6274320 Rothberg et al. Aug 2001 B1
6274351 Peponnet Aug 2001 B1
6277604 Peponnet Aug 2001 B1
6280954 Ulfendahl Aug 2001 B1
6284460 Fodor et al. Sep 2001 B1
6287821 Shi et al. Sep 2001 B1
6294336 Boyce-Jacino et al. Sep 2001 B1
6294337 Hayashizaki Sep 2001 B1
6306607 Williams Oct 2001 B2
6309601 Juncosa et al. Oct 2001 B1
6309701 Barbera-Guillem Oct 2001 B1
6309824 Drmanac Oct 2001 B1
6309836 Kwiatkowski Oct 2001 B1
6309886 Ambrose et al. Oct 2001 B1
6310189 Fodor et al. Oct 2001 B1
6312893 Van Ness et al. Nov 2001 B1
6316191 Drmanac et al. Nov 2001 B1
6322968 Head et al. Nov 2001 B1
6331439 Cherukuri et al. Dec 2001 B1
6333183 Evans et al. Dec 2001 B1
6335824 Overbeck Jan 2002 B1
6337185 Asp et al. Jan 2002 B1
6337188 Head et al. Jan 2002 B1
6342326 Milton Jan 2002 B1
6344325 Quake et al. Feb 2002 B1
6346379 Gelfand et al. Feb 2002 B1
6346413 Fodor et al. Feb 2002 B1
6355420 Chan Mar 2002 B1
6355432 Fodor et al. Mar 2002 B1
6361671 Mathies et al. Mar 2002 B1
6361937 Stryer Mar 2002 B1
6368562 Yao Apr 2002 B1
6368699 Gilbert et al. Apr 2002 B1
6383749 Bochkariov et al. May 2002 B2
6387626 Shi et al. May 2002 B1
6395232 McBride May 2002 B1
6395559 Swenson May 2002 B1
6397150 Izmailov May 2002 B1
6399364 Reeve et al. Jun 2002 B1
6401267 Drmanac Jun 2002 B1
6403311 Chan Jun 2002 B1
6403315 Drmanac Jun 2002 B1
6403317 Anderson Jun 2002 B1
6403320 Read et al. Jun 2002 B1
6403957 Fodor et al. Jun 2002 B1
6404907 Gilchrist et al. Jun 2002 B1
6406893 Knapp et al. Jun 2002 B1
6407858 Montagu Jun 2002 B1
6408878 Unger et al. Jun 2002 B2
6416952 Pirrung et al. Jul 2002 B1
6420169 Read et al. Jul 2002 B1
6423273 O'Mara Jul 2002 B1
6432634 Digby et al. Aug 2002 B1
6436641 Izmailov Aug 2002 B1
6436646 Nikiforov Aug 2002 B1
6440664 Digby et al. Aug 2002 B1
6440722 Knapp et al. Aug 2002 B1
6444106 Mcbride et al. Sep 2002 B1
6444173 Sjursen et al. Sep 2002 B1
6444424 Chatterjee et al. Sep 2002 B1
6444461 Knapp et al. Sep 2002 B1
6447724 Jensen et al. Sep 2002 B1
6448090 McBride Sep 2002 B1
6451536 Fodor et al. Sep 2002 B1
6479267 Davis et al. Nov 2002 B1
6485690 Pfost et al. Nov 2002 B1
6485909 Hong et al. Nov 2002 B1
6485944 Church et al. Nov 2002 B1
6495363 Bogdanov Dec 2002 B2
6506560 Hughes et al. Jan 2003 B1
6511803 Church et al. Jan 2003 B1
6514706 Von Kalle et al. Feb 2003 B1
6521428 Senapathy Feb 2003 B1
6524829 Seeger Feb 2003 B1
6528258 Russell Mar 2003 B1
6528288 Senapathy Mar 2003 B2
6537755 Drmanac Mar 2003 B1
6537757 Langmore et al. Mar 2003 B1
6546340 Lipshutz et al. Apr 2003 B2
6551784 Fodor et al. Apr 2003 B2
6551817 Besemer et al. Apr 2003 B2
6554987 Gilchrist et al. Apr 2003 B1
6555349 O'Donnell Apr 2003 B1
6558945 Kao May 2003 B1
6562566 Hoheisel May 2003 B1
6566059 Stanton, Jr. et al. May 2003 B1
6566515 McGall et al. May 2003 B1
6573047 Hung et al. Jun 2003 B1
6573374 Muehleger et al. Jun 2003 B1
6576424 Fodor et al. Jun 2003 B2
6576425 McGall et al. Jun 2003 B2
6579704 Short Jun 2003 B2
6582923 Stanton, Jr. et al. Jun 2003 B2
6585939 Dapprich Jul 2003 B1
6607888 Schwartz et al. Aug 2003 B2
6610482 Fodor et al. Aug 2003 B1
6613513 Parco et al. Sep 2003 B1
6623928 Van Ness et al. Sep 2003 B2
6627748 Ju et al. Sep 2003 B1
6632655 Mehta et al. Oct 2003 B1
6642001 Bolk et al. Nov 2003 B1
6664079 Ju et al. Dec 2003 B2
6719868 Schueller et al. Apr 2004 B1
6750018 Kambara et al. Jun 2004 B2
6762048 Williams Jul 2004 B2
6780591 Williams et al. Aug 2004 B2
6783938 Nygren et al. Aug 2004 B2
6787308 Balasubramanian et al. Sep 2004 B2
6818395 Quake et al. Nov 2004 B1
6908736 Densham Jun 2005 B1
6911345 Quake et al. Jun 2005 B2
20010024790 Kambara et al. Sep 2001 A1
20010044531 McGall et al. Nov 2001 A1
20010046681 Senapathy Nov 2001 A1
20020009744 Bogdanov Jan 2002 A1
20020012910 Weiss et al. Jan 2002 A1
20020015961 Kwiatkowski Feb 2002 A1
20020025529 Quake et al. Feb 2002 A1
20020032320 Burgess et al. Mar 2002 A1
20020034792 Kilger et al. Mar 2002 A1
20020039738 Williams et al. Apr 2002 A1
20020042112 Koster et al. Apr 2002 A1
20020045182 Singh et al. Apr 2002 A1
20020051992 Bridgham et al. May 2002 A1
20020053532 Quake et al. May 2002 A1
20020061529 Bridgham et al. May 2002 A1
20020072055 Jones Jun 2002 A1
20020086318 Manalis et al. Jul 2002 A1
20020102586 Ju et al. Aug 2002 A1
20020102595 Davis Aug 2002 A1
20020106673 Drmanac et al. Aug 2002 A1
20020115076 Williams Aug 2002 A1
20020115092 Rebek, Jr. Aug 2002 A1
20020119484 Weidenhammer et al. Aug 2002 A1
20020123046 Smith et al. Sep 2002 A1
20020132245 Boles et al. Sep 2002 A1
20020137046 Koster Sep 2002 A1
20020137052 Bridgham et al. Sep 2002 A1
20020137062 Williams et al. Sep 2002 A1
20020138205 Miller et al. Sep 2002 A1
20020142329 Matray et al. Oct 2002 A1
20020142333 Gelfand et al. Oct 2002 A1
20020146704 Head et al. Oct 2002 A1
20020146726 Matray et al. Oct 2002 A1
20020150903 Koster Oct 2002 A1
20020150938 Kneipp et al. Oct 2002 A1
20020164629 Quake et al. Nov 2002 A1
20020168642 Drukier Nov 2002 A1
20020168678 Williams et al. Nov 2002 A1
20020172948 Perlin Nov 2002 A1
20020177129 Paabo et al. Nov 2002 A1
20020182601 Sampson et al. Dec 2002 A1
20020192661 Paabo et al. Dec 2002 A1
20020192662 Boyce-Jacino et al. Dec 2002 A1
20020192691 Drmanac Dec 2002 A1
20020197618 Sampson Dec 2002 A1
20030003272 Laguitton Jan 2003 A1
20030003490 Fan et al. Jan 2003 A1
20030003498 Digby et al. Jan 2003 A1
20030008285 Fischer Jan 2003 A1
20030008413 Kim et al. Jan 2003 A1
20030017461 Singh et al. Jan 2003 A1
20030022207 Balasubramanian et al. Jan 2003 A1
20030027140 Ju et al. Feb 2003 A1
20030036080 Jensen et al. Feb 2003 A1
20030044778 Goelet et al. Mar 2003 A1
20030044779 Goelet et al. Mar 2003 A1
20030044781 Korlach et al. Mar 2003 A1
20030044816 Denison et al. Mar 2003 A1
20030054181 Swerdlow et al. Mar 2003 A1
20030054361 Heller Mar 2003 A1
20030058440 Scott et al. Mar 2003 A1
20030058799 Yamakawa et al. Mar 2003 A1
20030059778 Berlin et al. Mar 2003 A1
20030060431 Simmonds et al. Mar 2003 A1
20030064366 Hardin et al. Apr 2003 A1
20030064398 Barnes Apr 2003 A1
20030064483 Shaw et al. Apr 2003 A1
20030087237 Hong et al. May 2003 A1
20030087300 Knapp et al. May 2003 A1
20030092005 Levene et al. May 2003 A1
20030092007 Gibbs et al. May 2003 A1
20030096258 Fu et al. May 2003 A1
20030100006 Senapathy May 2003 A1
20030104437 Barnes et al. Jun 2003 A1
20030104466 Knapp et al. Jun 2003 A1
20030108867 Chee et al. Jun 2003 A1
20030138809 Williams et al. Jul 2003 A1
20030147344 Rothberg et al. Aug 2003 A1
20030162213 Fuller et al. Aug 2003 A1
20030186227 Balasubramanian et al. Oct 2003 A1
20030186255 Williams et al. Oct 2003 A1
20030190627 Zhao et al. Oct 2003 A1
20030190647 Odera Oct 2003 A1
20030190663 Yang et al. Oct 2003 A1
20030194722 Odedra et al. Oct 2003 A1
20030194740 Williams Oct 2003 A1
20030215862 Wallace et al. Nov 2003 A1
20040009487 Kadushin et al. Jan 2004 A1
20040014096 Anderson et al. Jan 2004 A1
20040029115 Dower et al. Feb 2004 A9
20040038206 Zhang et al. Feb 2004 A1
20040054162 Hanna Mar 2004 A1
20040096853 Mayer May 2004 A1
20040106110 Balasubramanian et al. Jun 2004 A1
20040126770 Kumar et al. Jul 2004 A1
20050014175 Quake et al. Jan 2005 A1
20050100932 Lapidus et al. May 2005 A1
20050116262 Lapidus Jun 2005 A1
20050147992 Quake et al. Jul 2005 A1
20050170367 Quake et al. Aug 2005 A1
20050239085 Buzby et al. Oct 2005 A1
Foreign Referenced Citations (174)
Number Date Country
10256898 Sep 2004 DE
0223618 May 1987 EP
0412883 Feb 1991 EP
0579997 Jan 1994 EP
0703364 Mar 1996 EP
0706004 Apr 1996 EP
0779436 Jun 1997 EP
0845603 Jun 1998 EP
0932700 Aug 1999 EP
0946752 Oct 1999 EP
0955085 Nov 1999 EP
0999055 May 2000 EP
0706004 Aug 2003 EP
2155152 Sep 1985 GB
2308460 Jun 1997 GB
2400518 Oct 2004 GB
9500589 Feb 1995 SE
8903432 Apr 1989 WO
8909283 Oct 1989 WO
9013666 Nov 1990 WO
9015070 Dec 1990 WO
9106678 May 1991 WO
9210092 Jun 1992 WO
9210587 Jun 1992 WO
9305183 Mar 1993 WO
9306121 Apr 1993 WO
9321340 Oct 1993 WO
9512608 May 1995 WO
9527080 Oct 1995 WO
9604547 Feb 1996 WO
9612014 Apr 1996 WO
9612039 Apr 1996 WO
9627025 Sep 1996 WO
9702488 Jan 1997 WO
9722076 Jun 1997 WO
9723650 Jun 1997 WO
9737041 Oct 1997 WO
9739150 Oct 1997 WO
9740184 Oct 1997 WO
9741258 Nov 1997 WO
9741259 Nov 1997 WO
9742348 Nov 1997 WO
9800708 Jan 1998 WO
9802575 Jan 1998 WO
9803684 Jan 1998 WO
9807069 Feb 1998 WO
9813523 Apr 1998 WO
9808978 May 1998 WO
9820019 May 1998 WO
9820020 May 1998 WO
9820166 May 1998 WO
9821361 May 1998 WO
9827228 Jun 1998 WO
9828440 Jul 1998 WO
9833939 Aug 1998 WO
9840520 Sep 1998 WO
9841650 Sep 1998 WO
9841657 Sep 1998 WO
9844152 Oct 1998 WO
9845481 Oct 1998 WO
9853300 Nov 1998 WO
9854669 Dec 1998 WO
9855593 Dec 1998 WO
9901768 Jan 1999 WO
9905221 Feb 1999 WO
9905315 Feb 1999 WO
9906422 Feb 1999 WO
9913109 Mar 1999 WO
9913110 Mar 1999 WO
9909616 Apr 1999 WO
9917093 Apr 1999 WO
9919516 Apr 1999 WO
9924797 May 1999 WO
9927137 Jun 1999 WO
9931278 Jun 1999 WO
9937810 Jul 1999 WO
9939001 Aug 1999 WO
9940105 Aug 1999 WO
9940223 Aug 1999 WO
9941410 Aug 1999 WO
0030591 Sep 1999 WO
9944045 Sep 1999 WO
9945153 Sep 1999 WO
9947539 Sep 1999 WO
9947706 Sep 1999 WO
9953423 Oct 1999 WO
9957321 Nov 1999 WO
9961888 Dec 1999 WO
9964437 Dec 1999 WO
9964840 Dec 1999 WO
9965938 Dec 1999 WO
9966076 Dec 1999 WO
9966313 Dec 1999 WO
0000637 Jan 2000 WO
0006770 Feb 2000 WO
0009753 Feb 2000 WO
0011223 Mar 2000 WO
0017397 Mar 2000 WO
0026935 May 2000 WO
0034523 Jun 2000 WO
0037680 Jun 2000 WO
0040750 Jul 2000 WO
0040758 Jul 2000 WO
0042223 Jul 2000 WO
0043540 Jul 2000 WO
0043752 Jul 2000 WO
0050642 Aug 2000 WO
0053805 Sep 2000 WO
0053812 Sep 2000 WO
0056937 Sep 2000 WO
0058507 Oct 2000 WO
0058516 Oct 2000 WO
0068410 Nov 2000 WO
0070073 Nov 2000 WO
0071755 Nov 2000 WO
0079007 Dec 2000 WO
01001025 Jan 2001 WO
0116375 Mar 2001 WO
0123610 Apr 2001 WO
0124937 Apr 2001 WO
0125480 Apr 2001 WO
0131055 May 2001 WO
0132930 May 2001 WO
0138574 May 2001 WO
0148184 May 2001 WO
0142496 Jun 2001 WO
0157248 Aug 2001 WO
0157249 Aug 2001 WO
0161044 Aug 2001 WO
0164838 Sep 2001 WO
0175154 Oct 2001 WO
0179536 Oct 2001 WO
0185991 Nov 2001 WO
0192284 Dec 2001 WO
0196607 Dec 2001 WO
0200343 Jan 2002 WO
0202584 Jan 2002 WO
0202795 Jan 2002 WO
0202813 Jan 2002 WO
0203305 Jan 2002 WO
0204680 Jan 2002 WO
0220836 Mar 2002 WO
0220837 Mar 2002 WO
0227032 Apr 2002 WO
0229106 Apr 2002 WO
02030486 Apr 2002 WO
0235441 May 2002 WO
0236832 May 2002 WO
0244414 Jun 2002 WO
02061126 Aug 2002 WO
02061127 Aug 2002 WO
02072779 Sep 2002 WO
02072892 Sep 2002 WO
02077694 Oct 2002 WO
02079519 Oct 2002 WO
02088381 Nov 2002 WO
02088382 Nov 2002 WO
02097113 Dec 2002 WO
02099398 Dec 2002 WO
03002767 Jan 2003 WO
03016565 Feb 2003 WO
03021010 Feb 2003 WO
03020895 Mar 2003 WO
03020968 Mar 2003 WO
03031947 Apr 2003 WO
03044678 May 2003 WO
03048178 Jun 2003 WO
03048991 Jun 2003 WO
03062897 Jul 2003 WO
03106642 Dec 2003 WO
04061119 Jul 2004 WO
04074503 Sep 2004 WO
05047523 May 2005 WO
05080605 Sep 2005 WO
Related Publications (1)
Number Date Country
20060147942 A1 Jul 2006 US